Natus completes acquisition of Nicolet neurodiagnostic business

Tuesday, July 3, 2012 10:32 AM

Natus Medical, a San Carlos, Calif.-based provider of healthcare products, has completed the acquisition of the Nicolet neurodiagnostic business from CareFusion for an approximate $58 million cash.

 “The Nicolet acquisition strengthens our leadership position in neurodiagnostic and monitoring products,” said Jim Hawkins, CEO of Natus. “The Nicolet portfolio of electroencephalography (EEG) and electromyography (EMG) systems and related accessories, as well as vascular and obstetric Doppler sensors and connectivity products, will allow us to bring additional value to our customers as well as adding to our customer base around the world.”

Based in Middleton, Wis., the Nicolet neurodiagnostic business employs more than 400 people worldwide and generated sales of approximately $95 million in 2011.

“We expect this acquisition to be marginally accretive to non-GAAP earnings in the fourth quarter of this year and to significantly improve our profitability in 2013,” said Hawkins. “Integration activities should be substantially completed by the end of 2012.”

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs